SAGES Magazine

TheapprovedMezavantprofessional information shouldbe consultedbeforeprescribing. 5-ASA:5-acetyl salicylicacid Adcock IngramLimited.Reg.No.1949/034385/06.PrivateBagX69,Bryanston,2021,SouthAfrica. CustomerCare:0860ADCOCK/232625 .www.adcock.com.2022021110184020.February2 022.C-APROM/ZA/MEZ/0003. References: 1. Mezavant approved professional information, August 2013. 2. Tenjarla S, RomasantaV, Zeijdner E,Villa R, Moro L. Release of 5-aminosalicylate from an MMX mesalamine tablet during transit through a simulated gastrointestinal tract system. Advances in Therapy 2007;24(4):826-840. 3. YangLPH,McCormackPL.MMX®Mesalazine:A reviewof itsuse in themanagementofmild tomoderateulcerative colitis. Drugs 2011;71(2):221-235. 4. BrunnerM,AssandriR,KletterK,TschurlovitsM,CorradoMe,VillaR, etal. Gastrointestinal transitand5-ASA release fromanewmesalazineextended- release formulation.AlimentPharmacolTher.2003;17:395–402. 5. TenjarlaS,AbinusawaA. In-vitro characterizationof5-aminosalicylicacid release fromMMXmesalamine tabletsanddeterminationof tablet coating thickness. AdvTher 2011;28(1):62-72. Mezavant® (enteric coated,prolonged-release tablet.)Each tablet containsmesalazine1200mg.Reg.No.45/11/0463.TAKEDA (Pty)Ltd.Reg.No.:1982/011215/07.BuildingA,MonteCircle,64MontecasinoBoulevard,Fourways,2191,SouthAfrica .Tel:+27 (0)115143000. Fax :+27 (0)115143001. MarketedbyAdcock IngramHealthcare (Pty)Ltd.Reg.No.:2007/019928/07.PrivateBagX69,Bryanston,2021,SouthAfrica.CustomerCare:0860ADCOCK/232625 .www.adcock.com.For fullprescribing information refer to theprofessional informationapprovedby themedicines regulatoryauthority. Mezavant ® is a valuable option in the management of patients with mild to moderate ulcerative colitis 3 Hydrophilic matrix 2,4 Prolonged drug release 2 Gastro-resistant coating 2 Lipophilic matrix 2 450 min 390 min 330 min Rectum Small Intestine Anus Large Intestine (Colon) Sigmoid Colon Stomach 450 min 390 min 330 min Rectum Small Intestine Anus Large Intestine (Colon) Sigmoid Colon Stomach MMX ® TECHNOLOGY FOR PROLONGED DRUG RELEASE 1,2,4,5 Scintigraphic images showing the passage of a single 1.2 g radiolabelled Mesalazine tablet in a healthy volunteer* 4 DELIVERS MESALAZINE 5-AMINOSALICYLATE (5-ASA) THROUGHOUT THE COLON 1,2,4,5 Adapted from Brunner M, et al. 2003 4 * Gastrointestinal transit was followed by gamma-scintigraphy after single-dose application of tablets containing 1200 mg mesalazine to 12 healthy male volunteers. 4 Prolonged release mesalazine for patients with mild-to-moderate ulcerative colitis 1,2 2